Tempus AI: 3 Key Takeaways for Long-Term Investors

Cover art for Tempus AI: 3 Key Takeaways for Long-Term Investors

TL;DR: Tempus AI's third-quarter 2026 earnings report $411.5M revenue up 23% YoY with $193M data licensing and $80M oncology ASP gains expected by 2027. Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors. Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year.

The Motley Fool TeamNov 19, 2026

From · · · 50s

TL;DR: Tempus AI: 3 Key Takeaways for Long-Term Investors

Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors.

Tempus AI's third-quarter 2026 earnings report $411.5M revenue up 23% YoY with $193M data licensing and $80M oncology ASP gains expected by 2027. Tempus AI's 2026 earnings show $193M data deals and $80M oncology pricing boost for long-term investors. Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year.

  • Q3 2026 Revenue
  • Multiyear Biopharma Deals
  • Oncology Pricing Boost
  • Positive Adjusted EBITDA

Read the story version — the same reporting as a swipeable deck of 4 cards.

Read the original on The Motley Fool

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on tempus ai and related topics.